Medigen Biotechnology Cash Flow Conversion Efficiency
Medigen Biotechnology cash flow conversion efficiency. Based on the latest financial reports, Medigen Biotechnology (3176) has a cash flow conversion efficiency ratio of -0.004x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$-18.91 Million ≈ $-595.86K USD) by net assets (NT$4.90 Billion ≈ $154.29 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Medigen Biotechnology (2003–2024)
Cash flow conversion efficiency of Medigen Biotechnology from 2003 to 2024. This chart illustrates how Medigen Biotechnology's cash flow conversion efficiency has evolved over time, based on yearly financial data. View 3176 stock price for real-time trading data and today's change.
Medigen Biotechnology Cash Flow Conversion Ratio Explained
Medigen Biotechnology cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Medigen Biotechnology Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Medigen Biotechnology ranked by their cash flow conversion efficiency. Also see Medigen Biotechnology market cap and net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Kyeryong Const
KO:013580
|
0.154x |
|
BRC Group Holdings, Inc.
NASDAQ:RILY
|
1.643x |
|
Metal Powder Works Ltd
AU:MPW
|
-0.309x |
|
ANDREW PELLER LTD A
F:ANJ
|
0.013x |
|
Userjoy Technology Co Ltd
TWO:3546
|
0.066x |
|
The E&M Co. Ltd
KQ:089230
|
-0.116x |
|
Jean Co Ltd
TW:2442
|
-0.131x |
|
Heran Co Ltd
TW:5283
|
0.153x |
Annual Cash Flow Conversion Efficiency for Medigen Biotechnology (2003–2024)
The table below shows the annual cash flow conversion efficiency of Medigen Biotechnology from 2003 to 2024. Review 3176 FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | NT$5.04 Billion ≈ $158.73 Million |
NT$37.92 Million ≈ $1.19 Million |
0.008x | +106.61% |
| 2023-12-31 | NT$5.00 Billion ≈ $157.44 Million |
NT$-569.40 Million ≈ $-17.94 Million |
-0.114x | +34.61% |
| 2022-12-31 | NT$6.47 Billion ≈ $203.87 Million |
NT$-1.13 Billion ≈ $-35.53 Million |
-0.174x | -316.41% |
| 2021-12-31 | NT$6.43 Billion ≈ $202.46 Million |
NT$517.45 Million ≈ $16.30 Million |
0.081x | +153.97% |
| 2020-12-31 | NT$4.50 Billion ≈ $141.76 Million |
NT$-671.38 Million ≈ $-21.15 Million |
-0.149x | +28.47% |
| 2019-12-31 | NT$2.69 Billion ≈ $84.60 Million |
NT$-560.17 Million ≈ $-17.65 Million |
-0.209x | -15.80% |
| 2018-12-31 | NT$2.94 Billion ≈ $92.66 Million |
NT$-529.82 Million ≈ $-16.69 Million |
-0.180x | -25.74% |
| 2017-12-31 | NT$3.18 Billion ≈ $100.19 Million |
NT$-455.62 Million ≈ $-14.35 Million |
-0.143x | -8.16% |
| 2016-12-31 | NT$3.54 Billion ≈ $111.46 Million |
NT$-468.61 Million ≈ $-14.76 Million |
-0.132x | -255.98% |
| 2015-12-31 | NT$3.46 Billion ≈ $109.14 Million |
NT$294.18 Million ≈ $9.27 Million |
0.085x | -31.58% |
| 2005-12-31 | NT$650.39 Million ≈ $20.49 Million |
NT$80.72 Million ≈ $2.54 Million |
0.124x | -76.13% |
| 2003-12-31 | NT$856.65 Million ≈ $26.99 Million |
NT$445.46 Million ≈ $14.03 Million |
0.520x | -- |
About Medigen Biotechnology
Medigen Biotechnology Corp., a biopharmaceutical company, engages in the research and development of new drugs and vaccines, cell therapy, advanced nucleic acid testing, generic drugs, medical beauty, and vaccine-related products in Taiwan. It offers cell therapies, such as MAGICELL-NK, which are natural killer cells; and MAGICELL-GDT, which are T cells. It also develops OBP-301 that has complete… Read more